4,6-二氯-5-甲氧基嘧啶-2-胺 | 13428-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,6-二氯-5-甲氧基嘧啶-2-胺
• 英文名称: 4,6-Dichloro-5-methoxypyrimidin-2-amine
• CAS: 13428-25-6
• 化学式: C₅H₅Cl₂N₃O
• 分子量: 194.02
• InChiKey: HJPXRPSGMWLORH-UHFFFAOYSA-N

物化性质

• 熔点：
  216 °C(Solv: water, 80% (7732-18-5); ethanol (64-17-5))
• 沸点：
  374.2±52.0 °C(Predicted)
• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS
  申请人：Apros Therapeutics, Inc.

  公开号：US20180155298A1

  公开（公告）日：2018-06-07

  The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.

  本公开涉及一类具有免疫调节性质的嘧啶衍生物，通过TLR7发挥作用，对治疗病毒感染和癌症有用。
• [EN] SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] PYRIMIDINE SUBSTITUÉE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021063852A1

  公开（公告）日：2021-04-08

  The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供具有通式的新化合物：其中R1至R4、L1、L2和X如本文所述，包括这些化合物的组合物和使用这些化合物的方法。
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
  申请人：VERTEX PHARMA

  公开号：WO2022076627A1

  公开（公告）日：2022-04-14

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies and combination pharmaceuticals employing those modulators, and processes and intermediates for making such modulators.

  本公开提供囊性纤维化跨膜传导调节因子（CFTR）的调节剂，其具有以下核心结构：，包含至少一种这样的调节剂的药物组合物，使用这样的调节剂和药物组合物治疗CFTR介导的疾病，包括囊性纤维化的方法，使用这些调节剂的组合疗法和组合药物，以及制造这些调节剂的过程和中间体。
• PYRAZOLE DERIVATIVES AND SALTS THEREOF
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1103551A1

  公开（公告）日：2001-05-30

  This invention provides compounds having antitumor effect, namely a compound represented by the following formula (I) or (Ia) having various substituents in which G and G1 are condensed tricyclic heterocyclic rings or salts thereof, and a compound represented by the following formula (Ib) having various substituents or salts thereof.

  本发明提供了具有抗肿瘤作用的化合物，即具有各种取代基的下式（I）或（Ia）所代表的化合物（其中 G 和 G1 是缩合三环杂环）或其盐，以及具有各种取代基的下式（Ib）所代表的化合物或其盐。
• BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Shionogi & Co., Ltd

  公开号：EP3527568A1

  公开（公告）日：2019-08-21

  Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. A compound represented by Formula (I): wherein Z1 is C(R4) or the like; R4 is a hydrogen atom or the like; Z2 is C(R5a)(R5a') or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then R5a' is absent; R5a and R5a' are each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Y1 is O or the like; R2a is a group represented by the formula: -(C(R2a')(R2b'))n-R1; R2b is a hydrogen atom or the like; R2a' and R2b' is each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.

  本文提供了一种对 P2X7 受体具有拮抗活性的新型化合物，以及一种对 P2X7 受体具有拮抗活性的药物组合物。由式（I）代表的化合物： 其中Z1是C(R4)或类似物；R4是氢原子或类似物；Z2是C(R5a)(R5a')或类似物；虚线表示键的存在或不存在；当虚线表示键的存在时，则R5a'不存在；R5a和R5a'各自独立地是氢原子或类似物；环Q是取代或未取代的5元非芳杂环或类似物；Y1是O或类似物；R2a是由式表示的基团：-(C(R2a')(R2b'))n-R1； R2b 是氢原子或类似物； R2a'和 R2b'各自独立地是氢原子或类似物； R1 是取代或未取代的芳香族碳环或类似物； X 是 N(R7a)或类似物；R7a 是氢原子或类似物；R3 是取代或未取代的芳香族羰基或类似物；n 是 0 至 4 的整数；和 m 是 0 至 4 的整数，或其药学上可接受的盐。